Table 1 Prediction of repeat biopsy results by PSAD and PSAV
From: Characterization of prostate cancer detected at repeat biopsy
| Â | Cancer (n = 23) | Non-Cancer (n = 104) | P | sensitivity | specificity | PPV | NPV |
|---|---|---|---|---|---|---|---|
PSAV (ng/ml year) | Â | Â | 0.0004 | 78% | 63% | 32% | 93% |
   ≥ 0.80 | 18 (78%) | 39 (37%) |  |  |  |  |  |
   <0.80 | 5 (22%) | 65 (63%) |  |  |  |  |  |
PSAD (ng/mL2) | Â | Â | 0.12 | 61% | 67% | 29% | 89% |
   ≥ 0.30 | 14 (61%) | 34 (33%) |  |  |  |  |  |
   <0.30 | 9 (39%) | 70 (67%) |  |  |  |  |  |
PSAV ≥ 0.80 and PSAD ≥ 0.30 | 12 (52%) | 15 (14%) | 6.2 × 10-5 | 52% | 86% | 44% | 89% |
PSAV ≥ 0.80 and PSAD < 0.30 | 6 (26%) | 24 (23%) |  |  |  |  |  |
PSAV < 0.80 and PSAD ≥ 0.30 | 2 (9%) | 19 (18%) |  |  |  |  |  |
PSAV < 0.80 and PSAD < 0.30 | 3 (13%) | 46 (44%) | 0.0054 | 87% | 44% | 26% | 94% |